From Phytochemistry to Drug Discovery: A Systematic Review of Multitarget Pharmacology and Lead Compound Prioritization of Piper crocatum Ruiz & Pav
Abstract
Piper crocatum Ruiz & Pav. (Piperaceae), commonly known as red betel, is a medicinal plant widely used in Southeast Asian traditional medicine and has attracted increasing interest due to its diverse pharmacological properties. However, the relationship between its phytochemical constituents, biological activities, molecular mechanisms, and drug discovery potential remains insufficiently integrated. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided review aimed to summarize the phytochemical constituents and pharmacological activities of P. crocatum and evaluate their relevance as potential lead structures for drug development. Literature published between 2000 and 2026 was retrieved from Scopus and PubMed. A total of 180 records were identified, and 102 eligible original studies reporting phytochemical and/or biological investigations of P. crocatum were included in the final analysis. Forty compounds have been reported from P. crocatum, including phenolic compounds, neolignans, flavonoids, terpenoids, and phytosterols. These constituents are associated with antimicrobial, antibiofilm, antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, anticancer, and immunomodulatory activities. Mechanistic evidence suggests that these effects involve modulation of oxidative stress, inflammatory signaling, microbial sterol biosynthesis, biofilm-related proteins, and metabolic enzymes such as α-glucosidase and pancreatic lipase. Among the…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Learning from First-Generation Qualitative Approaches in the IS Discipline: An Evolutionary View and Some Implications for Authors and Evaluators (PART 1/2)
- Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
- Prosthesis: New Technological Opportunities and Innovative Biomedical Devices
- The history and future of neural modeling for cochlear implants
- Ryanodine receptors: waking up from refractoriness
- Novel Transgenic Rabbit Model Sheds Light on the Puzzling Role of Matrix Metalloproteinase-12 in Atherosclerosis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.